Discontinued — last reported Q4 '25
Illumina Asia-Pacific, Middle East and Africa — Revenue increased by 0.9% to $112.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 2.8%, from $109.00M to $112.00M. Over 4 years (FY 2021 to FY 2025), Asia-Pacific, Middle East and Africa — Revenue shows a downward trend with a -4.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates successful market penetration, growing demand for genomic sequencing technology, or effective sales execution in these regions. A decrease may signal increased local competition, macroeconomic headwinds, or challenges in regulatory approval and adoption of high-throughput sequencing platforms.
This metric represents the total net sales generated from products and services within the Asia-Pacific, Middle East, an...
Peers in the life sciences and diagnostics sector typically report regional revenue to highlight geographic diversification and exposure to high-growth emerging markets.
ilmn_segment_asia_pacific_middle_east_and_africa_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $129.25M | $129.25M | $129.25M | $162.00M | $131.00M | $126.00M | $125.00M | $119.00M | $118.00M | $98.00M | $124.00M | $116.00M | $108.00M | $105.00M | $109.00M | $106.00M | $100.00M | $111.00M | $112.00M |
| QoQ Change | — | +0.0% | +0.0% | +25.3% | -19.1% | -3.8% | -0.8% | -4.8% | -0.8% | -16.9% | +26.5% | -6.5% | -6.9% | -2.8% | +3.8% | -2.8% | -5.7% | +11.0% | +0.9% |
| YoY Change | — | — | — | — | +1.4% | -2.5% | -3.3% | -26.5% | -9.9% | -22.2% | -0.8% | -2.5% | -8.5% | +7.1% | -12.1% | -8.6% | -7.4% | +5.7% | +2.8% |